The average annual costs of HIV ART regimens have escalated in recent years, with the average annual price of recommended ART regimens having jumped 34% since 2012 or 3.5 times the inflation rate. This finding (and more) is summarized in HIV Antiretroviral Therapy Costs in the United States, 2012-2018, a JAMA Network Research Letter. Note: (Access to the JAMA article requires sign-in or an account.)
The review takes Average Wholesale Price (AWP), a rather imprecise measure of costs actually incurred by both patients and insurers, given the plethora of rebates, discounts, and negotiated prices. Regardless, the data do provide a rough insight into what it will take to expand access to HIV therapy in order to end the HIV epidemic.
Learn more about Ryan White Part B AIDS Drug Assistance Programs (ADAPs) and how they are managing access and costs of HIV-related regimens for persons with little to no access to needed services, including HRSA-funded ADAP Technical Assistance